Clinical Research Directory
Browse clinical research sites, groups, and studies.
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Sponsor: Sun Yat-sen University
Summary
Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.
Official title: Multicenter Randomized Controlled Trial of Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
264
Start Date
2022-06-01
Completion Date
2028-06-01
Last Updated
2022-07-01
Healthy Volunteers
No
Conditions
Interventions
Gemcitabine
for induction chemotherapy
Cisplatin
for induction and concurrent chemotherapy
regular intensity-modulated radiotherapy
in active comparator arm
surgery
in experimental arm
Target-reduction intensity-modulated radiotherapy
in experimental arm
Locations (2)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China